Fukugawa Yoshiyuki, Namimoto Tomohiro, Toya Ryo, Saito Tetsuo, Yuki Hideaki, Matsuyama Tomohiko, Ikeda Osamu, Yamashita Yasuyuki, Oya Natsuo
Department of Radiation Oncology, Kumamoto University Hospital, Kumamoto 860-8556, Japan.
Acta Med Okayama. 2017 Feb;71(1):25-29. doi: 10.18926/AMO/54822.
Focal liver reaction (FLR) appears in the hepatobiliary-phase images of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI) following radiotherapy (RT). We investigated the threshold dose (TD) for FLR development in 13 patients with hepatocellular carcinoma (HCC) who underwent three-dimensional conformal radiotherapy (3D-CRT) with 45 Gy in 15 fractions. FLR volumes (FLRVs) were calculated based on planning CT images by referring to fused hepatobiliary- phase images. We also calculated the TD and the irradiated volumes (IVs) of the liver parenchyma at a given dose of every 5 Gy (IVdose) based on a dose-volume histogram (DVH). The median TD was 35.2 Gy. The median IV20, IV25, IV30, IV35, IV40, and IV45 values were 371.1, 274.8, 233.4, 188.6, 145.8, and 31.0 ml, respectively. The median FLRV was 144.9 ml. There was a significant difference between the FLRV and IV20, IV25, and IV45 (p<0.05), but no significant differences between the FLRV and IV30, IV35, or IV40. These results suggest that the threshold dose of the FLR is approx. 35 Gy in HCC patients who undergo 3D-CRT in 15 fractions. The percentage of the whole liver volume receiving a dose of more than 30-40 Gy (V30-40) is a potential candidate optimal DVH parameter for this fractionation schedule.
局灶性肝反应(FLR)出现在放疗(RT)后钆乙氧基苄基二乙烯三胺五乙酸增强磁共振成像(Gd-EOB-DTPA增强MRI)的肝胆期图像中。我们研究了13例肝细胞癌(HCC)患者在接受三维适形放疗(3D-CRT)、15次分割共45 Gy照射后发生FLR的阈值剂量(TD)。基于融合的肝胆期图像,通过参考计划CT图像计算FLR体积(FLRVs)。我们还根据剂量体积直方图(DVH)计算了每5 Gy给定剂量下肝实质的TD和照射体积(IVs)(IVdose)。TD的中位数为35.2 Gy。IV20、IV25、IV30、IV35、IV40和IV45的中位数分别为371.1、274.8、233.4、188.6、145.8和31.0 ml。FLRV的中位数为144.9 ml。FLRV与IV20、IV25和IV45之间存在显著差异(p<0.05),但FLRV与IV30、IV35或IV40之间无显著差异。这些结果表明,在接受15次分割3D-CRT的HCC患者中,FLR的阈值剂量约为35 Gy。接受超过30 - 40 Gy剂量(V30 - 40)的全肝体积百分比是该分割方案潜在的最佳DVH参数候选指标。